EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Galacto-Oligosaccharides Exert Bifidogenic Effects at Capsule-Compatible Ultra-Low Doses

Lucien F Harthoorn, Jasmine Heyse iD, Aurélien Baudot iD, Ingmar A J van Hengel iD, Pieter Van den Abbeele iD

Metabolites · 05.08.2025 · 15 (8) · 530

DOI: 10.3390/metabo15080530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Metabolites, online erschienen am 05.08.2025. Verfasst von Lucien F Harthoorn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clasado Biosciences Ltd., Imperium Building, Imperial Way, Worton Grange, Reading RG2 0TD, UK. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clasado Biosciences Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prebiotics are selectively used by host microorganisms to promote health. Because effective prebiotic doses (1.5–30 g/day) often require inconvenient delivery formats, this study aims to explore whether capsule-compatible doses of galacto-oligosaccharides (GOS) can effectively modulate the gut microbiome.

Methods

The impact of Bimuno® GOS (Reading, UK) at 0.5, 0.75, 1.83, and 3.65 g on the adult gut microbiome was assessed using the ex vivo SIFR® technology (n = 8), a clinically validated, bioreactor-based technology.

Results

The GOS were rapidly fermented and significantly increased beneficial Bifidobacterium species (B. adolescentis, B. bifidum, and B. longum), even at the lowest tested dose. In doing so, GOS strongly promoted SCFA production, particularly acetate (significant from 0.5 g) and butyrate (significant from 0.75 g). Gas production only mildly increased, likely as Bifidobacterium species do not produce gases. Based on the ability of the SIFR® technology to cultivate strictly anaerobic, hard-to-culture gut microbes, unlike in past in vitro studies, we elucidated that GOS also enriched specific Lachnospiraceae species. Besides Anaerobutyricum hallii, this included Bariatricus comes, Blautia species (B. massiliensis, Blautia_A, B. faecis), Oliverpabstia intestinalis, Mediterraneibacter faecis, and Fusicatenibacter species. Finally, GOS also promoted propionate (significant from 0.75 g), linked to increases in Phocaeicola vulgatus.

Conclusions

GOS displayed prebiotic potential at capsule-compatible doses, offering greater flexibility in nutritional product formulation and consumer convenience. Notably, the strong response at the lowest dose suggests effective microbiome modulation at lower levels than previously expected.

Schlagwörter

Stichwörter der Autor:innen

BifidobacteriaceaeGOSLachnospiraceaeSCFASIFR® technologyprebiotic

Autor:innen und Institutionen

  • Clasado Biosciences Ltd., Imperium Building, Imperial Way, Worton Grange, Reading RG2 0TD, UK.
  • Cryptobiotix SA, Technologiepark-Zwijnaarde 82, 9052 Ghent, Belgium.

ORCID-Profile: Jasmine Heyse, Aurélien Baudot, Ingmar A J van Hengel, Pieter Van den Abbeele

Förderung

  • Clasado Biosciences Ltd.

Zitieren

APA

Harthoorn, L. F., Heyse, J., Baudot, A., van Hengel, I. A. J., & Van den Abbeele, P. (2025). Galacto-Oligosaccharides Exert Bifidogenic Effects at Capsule-Compatible Ultra-Low Doses. Metabolites, 15(8), 530. https://doi.org/10.3390/metabo15080530

Vancouver

Harthoorn LF, Heyse J, Baudot A, van Hengel IAJ, Van den Abbeele P. Galacto-Oligosaccharides Exert Bifidogenic Effects at Capsule-Compatible Ultra-Low Doses. Metabolites. 2025;15(8):530. doi:10.3390/metabo15080530

BibTeX
@article{Harthoorn2025,
  author = {Harthoorn, Lucien F and Heyse, Jasmine and Baudot, Aurélien and van Hengel, Ingmar A J and Van den Abbeele, Pieter},
  title = {Galacto-Oligosaccharides Exert Bifidogenic Effects at Capsule-Compatible Ultra-Low Doses},
  journal = {Metabolites},
  year = {2025},
  volume = {15},
  number = {8},
  pages = {530},
  doi = {10.3390/metabo15080530}
}
Kostenlos starten →